Attapon Cheepsattayakorn^1-4*, Ruangrong Cheepsattayakorn⁵ and Porntep Siriwanarangsun²

¹Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
²Faculty of Medicine, Western University, Pathumtani Province, Thailand
³10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
⁴Department of Disease Control, Ministry of Public Health, Thailand
⁵Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

Received: June 17, 2024; Published: July 01, 2024

Abstract

recent retrospective study in the United States by using electronic health records (EHR) among positive-SARS-CoV-2 patients during March 2021 to February 2022. Both unvaccinated (161,531) and vaccinated (161,531) COVID-19 patients were matched on age, sex, acute infection severity, test date, and location. The analyzed data revealed that, except mental health disorders, vaccinated patients had lower risk of all post-COVID-19 conditions (PCC) categories (relative risk (RR): 1.06, 95% confidential interval (CI): 1.02-1.10) [1]. COVID-19 vaccination was related to lower risk of cardiovascular (RR: 0.88, 95% : 0.83-0.94), blood and hematologic (RR: 0.79, 95% CI: 0.71-0.89), more than 10% of lower risk of sensory (RR: 0.90, 95% CI: 0.86-0.95), skin and subcutaneous (RR: 0.69, 95% CI: 0.66-.72)

References

1. Malden DE., et al. “Post-COVID conditions following COVID-19 vaccination : a retrospective matched cohort study of patients with SARS-CoV-2 infection”. Nature Communications 15 (2024): 4101.
2. Martinez DR., et al. “The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses”. Science Translational Medicine748 (2024).

Citation

Citation: Attapon Cheepsattayakorn., et al. “GS-5245, A New Oral Nucleoside Prodrug is Efficacious Against SARS-CoV-2 and Other Coronaviruses and Post-COVID-19 Conditions After COVID-19 Vaccination".Acta Scientific Microbiology 7.8 (2024): 01-03.

Copyright

Copyright: © 2024 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.